A recent preclinical study demonstrated that combining cytotoxic agents with CTLA4 inhibition and CD40 agonists may be more effective than targeting multiple checkpoints on T cells, especially in cold lesions as most TN breast tumors [51, 52]. Here, CTLA4 is linked to breast neoplasm.